Stomach Cancer Drugs Market To Find Better Growth with US$ 6.6 Billion By 2026 | CAGR: 5.4%: Coherent Market Insights
Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Global Stomach Cancer Drugs Market, by Therapy Type (Kinase Inhibitors, Nucleoside Metabolic Inhibitors, Anthracyclines, Microtubule Inhibitors, VEGF Antibodies, HER2 Receptor Antagonists, Car T Cell Therapy), By Application (Adenocarcinomas, Gastrointestinal Stromal Tumors, and Carcinoid Tumors), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 4.0 billion in 2017, and is estimated to exhibit a CAGR of 5.4% over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2667
The increasing number of food and drug administration (FDA) approvals of biosimilars and developing pipeline of new drug for treatment of stomach cancer is one of the major factors that is expected to drive the stomach cancer drugs market growth over the forecast period. For instance, in January 2019, the U.S. FDA approved South Korea’s Samsung Bioepis’ Ontruzant (trastuzumab biosimilar), indicated for the treatment of metastatic gastric cancer or gastro-esophageal junction adenocarcinoma. Samsung Bioepis is a joint venture between Samsung Biologics and Biogen. The biosimilar was also approved by the European Commission (EC) in November 2017.
Various key players such as Pfizer Inc., Merck & Co., Bristol-Meyer Squibb, and Eli Lilly & Company are focused on drugs that are in the pipeline such as Ipilimumab and Nivolumab and are expected to launch in the near future. For instance, in 2018, Bristol-Meyer Squibb’s Opdivo (Nivolumab) intravenous infusion injection is in the development pipeline. It is in phase 3 for treatment of stomach cancer and is expected to be launched in the U.S., Europe, and South Korea.
Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2667
Moreover, emerging research, developmental studies, and clinical trials to understand stomach cancer better, coupled with drug development are the factors that are further expected to drive the market growth over the forecast period. One of the most recent updates of clinical trials for stomach cancer in March 2019, include research on Helicobacter pylori eradication for gastric cancer prevention in the general population. This research is being sponsored by National Cancer Center, Korea and has entered into phase 3 showing positive results using bismuth-based quadruple therapy. Furthermore, in December 2018, Korean South West Oncology Group initiated a clinical trial on efficacy and safety of combination therapy with ramucirumab, paclitaxel, and trastuzumab biosimilar as a second line treatment of HER2 positive metastatic gastric cancer after failure of first line chemotherapy including trastuzumab. This study is in phase 2 and is expected to complete in 2022.
Browse 38 Market Data Tables and 27 Figures spread through 178 Pages and in-depth TOC on “Stomach Cancer Drugs Market, by Therapy Type (Kinase Inhibitors, Nucleoside Metabolic Inhibitors, Anthracyclines, Microtubule Inhibitors, VEGF Antibodies, HER2 Receptor Antagonists, Car T Cell Therapy), By Application (Adenocarcinomas, Gastrointestinal Stromal Tumors, and Carcinoid Tumors), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026″
To know the latest trends and insights related to Stomach Cancer Drugs market press release, click the link below: https://bit.ly/3059ujA
Additionally, several key players in the stomach cancer drugs market are focused on adopting strategic partnerships and collaborations, in order to gain significant market share. For instance, in October 2016, Teva Pharmaceuticals entered into partnership with Celltrion Healthcare Co. Ltd to commercialize biosimilar versions of Roche’s Herceptin to strengthen their product portfolio and fill a gap in its biosimilars pipeline.
Key Takeaways of the Stomach Cancer Drugs Market:
- The global stomach cancer drugs market is expected to exhibit a CAGR of 5.4% over the forecast period (2018-2026), attributed to increasing research & development activities, and demand for genomic and repertoire sequencing-based research.
- On the basis of therapy type, the Car T cells segment are expected account for significant market share over the forecast period. For instance, in 2017, pembrolizumab (Keytruda) the immunotherapy agent was approved by the U.S. Food and Drug Administration (FDA) to treat stomach cancer in some patients, whose previous treatment did not work or stopped working, and it proved to be better than chemotherapy.
- Key players operating in the global stomach cancer drugs market include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb (BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation, Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2667
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire